2. Non–squamous non–small cell lung cancer,with carboplatin and paclitaxel
for first line treatment of un-resectable, locally advanced, recurrent or
3. Metastatic breast cancer,with paclitaxel for treatment of patients who have:
not received chemotherapy for metastatic HER2–negative breast cancer.
– Effectiveness based on improvement in progression–free survival. No data available demonstrating improvement in disease–related symptoms or survival with Avastin.
– Not indicated for disease progression following anthracycline and taxane chemotherapy administered for metastatic disease.
4. Glioblastoma, as a single agent for adult patients with progressive disease following prior therapy.
– Effectiveness based on improvement in objective response rate. No data available demonstrating improvement in disease–related symptoms or survival with Avastin.
5. Metastatic renal cell carcinoma with interferon alfa.
Most common adverse reactions incidence (>10% and at least twice the control arm rate) are epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, rectal hemorrhage, lacrimation disorder, back pain and exfoliative dermatitis.